Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kohei Shitara

Showing results (1-10 of 375) with videos related to

Pageof 38
Sort By:
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|October 5, 2016
Chemotherapy for advanced gastric cancer: future perspective in JapanKohei Shitara
The New England Journal of Medicine|October 1, 2025
Trastuzumab Deruxtecan in Gastric Cancer. ReplyKohei Shitara
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2025
Reply to: Key Considerations for the Lenvatinib-Pembrolizumab-Chemotherapy Regimen in Advanced Gastric Cancer: Insights From LEAP-015Kohei Shitara,
Translational Gastroenterology and Hepatology|April 28, 2017
RAINFALL before RAINBOW-an illusion or reality?Kohei Shitara
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2026
Reply to: Can Pathologic Complete Response Serve as a Valid Surrogate End Point?Kohei Shitara
Future Oncology (London, England)|November 2, 2023
Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer: a plain language summary of the DESTINY-Gastric01 studyKohei Shitara
The New England Journal of Medicine|July 17, 2025
New Perioperative Strategy in Gastric CancerKohei Shitara
Lancet (London, England)|March 22, 2019
The KEYNOTE-061 trial - Authors' replyKohei Shitara, Xinqun Chen
Annals of the New York Academy of Sciences|March 23, 2018
Regulatory T cells: a potential target in cancer immunotherapyKohei Shitara, Hiroyoshi Nishikawa
Expert Opinion on Biological Therapy|April 2, 2021
Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancerSaori Mishima, Kohei Shitara
Pageof 38

Showing results (1-10 of 375) with videos related to

Sort By:
Pageof 38
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|October 5, 2016
Chemotherapy for advanced gastric cancer: future perspective in JapanKohei Shitara
The New England Journal of Medicine|October 1, 2025
Trastuzumab Deruxtecan in Gastric Cancer. ReplyKohei Shitara
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2025
Reply to: Key Considerations for the Lenvatinib-Pembrolizumab-Chemotherapy Regimen in Advanced Gastric Cancer: Insights From LEAP-015Kohei Shitara,
Translational Gastroenterology and Hepatology|April 28, 2017
RAINFALL before RAINBOW-an illusion or reality?Kohei Shitara
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2026
Reply to: Can Pathologic Complete Response Serve as a Valid Surrogate End Point?Kohei Shitara
Future Oncology (London, England)|November 2, 2023
Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer: a plain language summary of the DESTINY-Gastric01 studyKohei Shitara
The New England Journal of Medicine|July 17, 2025
New Perioperative Strategy in Gastric CancerKohei Shitara
Lancet (London, England)|March 22, 2019
The KEYNOTE-061 trial - Authors' replyKohei Shitara, Xinqun Chen
Annals of the New York Academy of Sciences|March 23, 2018
Regulatory T cells: a potential target in cancer immunotherapyKohei Shitara, Hiroyoshi Nishikawa
Expert Opinion on Biological Therapy|April 2, 2021
Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancerSaori Mishima, Kohei Shitara
Pageof 38